NDRA (ENDRA Life Sciences) Current Ratio: 0.64 (As of Mar. 2026) — 81% Below Median


NDRA ENDRA Life Sciences Inc NDRA
25 GF Score
Price $5.15
! 2 Warning Signs
View Full Analysis

What is ENDRA Life Sciences Current Ratio?

ENDRA Life Sciences NDRA +16.05% 25 Current Ratio is 0.64 as of Mar. 2026, which is 81% below its 10-year median of 3.42. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks worse than 86.92% on this metric.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ENDRA Life Sciences's current ratio for the quarter that ended in Mar. 2026 was 0.64.

ENDRA Life Sciences has a current ratio of 0.64. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If ENDRA Life Sciences has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for ENDRA Life Sciences's Current Ratio or its related term are showing as below:

NDRA' s Current Ratio Range Over the Past 10 Years
Min: 0.14   Med: 3.42   Max: 47.36
Current: 0.64

During the past 12 years, ENDRA Life Sciences's highest Current Ratio was 47.36. The lowest was 0.14. And the median was 3.42.

NDRA's Current Ratio is ranked worse than
86.92% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99 vs NDRA: 0.64

ENDRA Life Sciences  (NAS:NDRA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


ENDRA Life Sciences Current Ratio Related Terms


ENDRA Life Sciences Current Ratio Historical Data

* Premium members only.

The historical data trend for ENDRA Life Sciences's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENDRA Life Sciences Current Ratio Chart

ENDRA Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.83 3.16 3.36 5.68 1.29

ENDRA Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 3.21 1.31 1.29 0.64

NDRA vs NOTV, XWEL, ADVB: Current Ratio Comparison

For the Diagnostics & Research subindustry, ENDRA Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences Current Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Current Ratio distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's Current Ratio falls into.


NDRA
25GF Score
ENDRA Life Sciences Inc NDRA
Current Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENDRA Life Sciences Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

ENDRA Life Sciences's Current Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Current Ratio (A: Dec. 2025 )=Total Current Assets (A: Dec. 2025 )/Total Current Liabilities (A: Dec. 2025 )
=0.968/0.751
=1.29

ENDRA Life Sciences's Current Ratio for the quarter that ended in Mar. 2026 is calculated as

Current Ratio (Q: Mar. 2026 )=Total Current Assets (Q: Mar. 2026 )/Total Current Liabilities (Q: Mar. 2026 )
=0.537/0.835
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 0.64 mean?
ENDRA Life Sciences (NDRA) has a Current Ratio of 0.64 as of Mar. 2026. This is 81% below median its historical median of 3.42. Over the past decade, ENDRA Life Sciences' Current Ratio has ranged from 0.14 to 47.36. According to the industry distribution chart, ENDRA Life Sciences ranks #186 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 86.9%.
Is ENDRA Life Sciences' Current Ratio too high?
ENDRA Life Sciences' current Current Ratio of 0.64 is 81% below median its 10-year median of 3.42. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 47.36. The Medical Diagnostics & Research industry median Current Ratio is 1.99. ENDRA Life Sciences' value of 0.64 is 67.8% below this industry median. Based on the distribution chart, ENDRA Life Sciences ranks #186 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' Current Ratio compare to NOTV and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #186 out of 214 companies for Current Ratio. This places ENDRA Life Sciences in the lower half of its industry. The industry median Current Ratio is 1.99. ENDRA Life Sciences' value of 0.64 is 67.8% below this benchmark. Historically, ENDRA Life Sciences' own Current Ratio has ranged from 0.14 to 47.36 over the past decade. While the company's 10-year median is 3.42 vs. the industry median of 1.99, ENDRA Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.99, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ENDRA Life Sciences's current Current Ratio of 0.64 is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current Current Ratio is 0.64, which is 81% below median its own 10-year median of 3.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current Current Ratio of 0.64. The current Current Ratio is 0.64, which is 81% below median its 10-year median of 3.42 and 67.8% below the Medical Diagnostics & Research industry median of 1.99. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current Current Ratio is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ENDRA Life Sciences Business Description

Address 3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score

Get the complete analysis for NDRA

Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.15
Price